Table 5.
The median (range) values of methylation of studied CpG sites and chosen gene expression
| Analysis | AML patient MNCs Median (range) [number of patient] |
Control MNCs Median (range) [number of sample] |
|---|---|---|
| Methylation (%) | ||
| CG6 | 88.28 (5.00–99.53) [44] | 60.89 (48.75–70.89) [9] |
| CG7 | 74.45 (32.65–97.69) [42] | 60.21 (24.98–72.70) [9] |
| CG8 | 91.91 (30.43–99.65) [44] | 65.65 (60.11–82.36) [9] |
| CG9 | 55.34 (7.86–91.73) [42] | 46.53 (39.23–60.13) [8] |
| ZAC | 49.24 (18.96–71.97) [42] | 62.91 (46.50–78.97) [8] |
| IGF2-H19 | 70.20 (40.97–99.56) [45] | 78.12 (68.64–86.20) [9] |
| PEG3 | 67.18 (15.95–98.10) [42] | 67.41 (41.82–79.71) [9] |
| PEG1 | 56.29 (23.08–95.13) [45] | 66.74 (57.85–68.91) [9] |
| Expression (∆Ct) | ||
| DLK1 (× 10−7) | 50.98 (0.88–161,542.28) [29] | |
| MEG3 (× 10− 6) | 34.189 (1.36–19,339.85) [29] | |
| DLK1/MEG3 (× 10− 2) | 10.31 (0.20–1121.10) [29] | |